FOUND: 6 | Mind Blowing Facts

Pfizer Metsera Acquisition: What It Means for Patients and the Future of Weight Loss

Pfizer wins the $10B bid for Metsera, opening new avenues for obesity treatment and addressing unmet healthcare needs with next-generation medicines.

International Business Times UK · Nov 11, 2025

Pfizer clinches deal for obesity drug developer Metsea after a bidding war with Novo Nordisk

Pfizer has signed a deal to purchase Metsera Inc., an obesity drugmaker in the development stage, after winning a bidding war against Novo Nordisk

The Independent UK · Nov 8, 2025

Deal Dispatch: From A Founder Comeback To Billion-Dollar Bids, This Week In M&A And Bankruptcy

For the previous edition of Deal Dispatch, click here.

Benzinga · Nov 7, 2025

COVID jabs cut the risk of heart complications in kids

Vaccination has been associated with a smaller risk of rare heart conditions compared to COVID-19 infection in children, the largest study of its kind suggests.

AAP · Nov 4, 2025

Covid-19 jab causes fewer problems than the virus itself in youngsters – study

The new study was led by experts at UCL and the universities of Cambridge and Edinburgh.

The Independent UK · Nov 4, 2025

Novo, Pfizer Are Battling To Buy The Future Of Weight-Loss — But Viking Already Owns It

Pfizer Inc's (NYSE:PFE) lawsuit. Novo Nordisk A/S' (NYSE:NVO) counterbid. And in the middle of it all — a quiet $45 million position that might turn into Andreas Halvorsen's next masterstroke. After years of fighting from the sidelines of the Ozempic boom, Pfizer is finally throwing punches.

Benzinga · Nov 4, 2025

Pfizer, Novo Nordisk Intensify Fight For Metsera As Buyout Offers Continue To Climb

Adding more drama to Metsera Inc.’s (NASDAQ:MTSR) acquisition deal, Novo Nordisk A/S (NYSE:NVO) increased the deal proposal to $62.20 per share in cash, up from $56.50.

Benzinga · Nov 4, 2025

Dow Dips Over 400 Points; Pfizer Earnings Top Estimates

U.S. stocks traded lower this morning, with the Dow Jones index falling more than 400 points on Tuesday.

Benzinga · Nov 4, 2025

Pfizer COVID-19 vaccine sales drop 25% after confusing government guidance on the shot

Previously, fall is when Americans would typically receive their vaccines

The Independent UK · Nov 4, 2025

Pfizer's Core Drugs Offset COVID Revenue Drop, Lifts 2025 Profit Outlook Despite Tariffs

On Tuesday, Pfizer Inc. (NYSE:PFE) reported third-quarter 2025 adjusted earnings of 87 cents, compared to $1.06 a year ago, beating the consensus of 63 cents.

Benzinga · Nov 4, 2025